Drug Trial Radar · NCT05177666
a Prospective Registration Study for Patients With Advanced Refractory Solid Tumors
Last checked: Nov 20, 2026Latest source record: Jan 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
120
Planned (sponsor's estimate)
Start
Dec 30, 2021
Primary completion
Dec 30, 2023
Study completion Mar 30, 2024
Sponsor
- Lead sponsor
- The University of Hong Kong-Shenzhen HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Tianjin Happy Life Technology Co., Ltd.
- First posted
- Jan 4, 2022
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
Summary
As written by the sponsor on the registry.
This is a prospective registration study for patients with advanced refractory solid tumors. Patients who meet the eligibility criteria will be included to participate in the study, and baseline information to be collected after signed informed consent. Patients will choose for themselves whether to carry out targeted therapy or other appropriate treatment methods. And we plan to follow up for at least 12 months or until disease progression or death.
Conditions
- Feasibility
- Effectiveness
- Safety
- Targeted Molecular Therapy
Interventions
Targeted therapyDrug
Based on next-generation sequencing (NGS) detection, after discussion by the Molecular Steering Committee (MTB), intervention guidance suggestions are given based on domestic and foreign guidelines and clinical experience, and finally the patient and clinician jointly choose the treatment plan.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: 2021.11-2023.11
- Proportion of targeted therapy guided by tumor molecular characteristicsTime frame: 2021.11-2023.11
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.